- Home
- PTGX vs HTGC Comparison
PTGX vs HTGC Comparison
Compare PTGX & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- HTGC
- Stock Information
- Founded
- PTGX 2006
- HTGC 2003
- Country
- PTGX United States
- HTGC United States
- Employees
- PTGX N/A
- HTGC N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- HTGC Investment Managers
- Sector
- PTGX Health Care
- HTGC Finance
- Exchange
- PTGX Nasdaq
- HTGC Nasdaq
- Market Cap
- PTGX 5.0B
- HTGC 3.5B
- IPO Year
- PTGX 2016
- HTGC 2005
- Fundamental
- Price
- PTGX $84.63
- HTGC $17.68
- Analyst Decision
- PTGX Strong Buy
- HTGC Buy
- Analyst Count
- PTGX 9
- HTGC 8
- Target Price
- PTGX $86.44
- HTGC $21.13
- AVG Volume (30 Days)
- PTGX 938.5K
- HTGC 1.2M
- Earning Date
- PTGX 11-06-2025
- HTGC 10-30-2025
- Dividend Yield
- PTGX N/A
- HTGC 10.65%
- EPS Growth
- PTGX N/A
- HTGC N/A
- EPS
- PTGX 0.72
- HTGC 1.75
- Revenue
- PTGX $209,217,000.00
- HTGC $516,847,000.00
- Revenue This Year
- PTGX N/A
- HTGC $8.72
- Revenue Next Year
- PTGX $140.23
- HTGC $9.57
- P/E Ratio
- PTGX $117.81
- HTGC $10.08
- Revenue Growth
- PTGX N/A
- HTGC 4.54
- 52 Week Low
- PTGX $33.31
- HTGC $15.65
- 52 Week High
- PTGX $93.25
- HTGC $22.04
- Technical
- Relative Strength Index (RSI)
- PTGX 68.10
- HTGC 44.82
- Support Level
- PTGX $76.70
- HTGC $17.50
- Resistance Level
- PTGX $86.90
- HTGC $18.08
- Average True Range (ATR)
- PTGX 3.00
- HTGC 0.30
- MACD
- PTGX 0.40
- HTGC 0.03
- Stochastic Oscillator
- PTGX 84.27
- HTGC 36.81
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.